Program Schedule

New Anti-infective Clinical Trials That Will Change Your Practice

Thursday, October 9, 2014: 10:30 AM-12:00 PM
Room: The Pennsylvania Convention Center: 115-ABC

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • outline the results of recent, major anti-infective clinical trials
  • list strategies to incorporate the recent antimicrobial trial data in patient management
  • discuss the results of clinical trials for the new anti-infective agents including those with potential impact for changing clinical practice

Target Audience: Scientists, Researchers, Pharmacists, Nurses, Microbiologists, Members-in-training, Medical students and residents, Lab personnel, Investigators, Infectious diseases physicians, Infectious diseases pediatricians, Hospital administrators, Health care workers, Fellows, Clinicians, Academicians

Tracks: Pediatric ID, Investigative ID, Global ID, Adult ID

Moderators:  David Andes, MD, University of Wisconsin and Joshua Nosanchuk, MD, FIDSA, Albert Einstein College of Medicine

10:30 AM
Henry Chambers, MD, FIDSA
11:10 AM
Thomas Patterson
11:30 AM
Andrea Boggild, MD

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 CreditTM

ACPE Credits: ACPE 1.5 knowledge-based contact hours (0.15 CEU) of pharmacy CE

ACPE Number: 0221-9999-14-100-L01-P


D. Andes, Astellas: Consultant and Grant Investigator, Consulting fee and Research grant
Actelion: Grant Investigator, Research grant
Scynexis: Consultant, Consulting fee
Cubist: Consultant and Grant Investigator, Consulting fee and Research grant
Merck: Consultant, Consulting fee

J. Nosanchuk, None

H. Chambers, Merck: Shareholder, Purchased shares
AstraZeneca: Consultant, Consulting fee
Pfizer: Consultant, Consulting fee
Genentech: Seminar speaker, Speaker honorarium
Genentech: Investigator, Grant recipient
Cubist: Consultant, Consulting fee
Theravance: Consultant, Consulting fee

R. Whitley, None

T. Patterson, Astellas: Consultant and Scientific Advisor, Consulting fee
Merck: Consultant and Investigator, Research grant
Scynexis: Scientific Advisor, Consulting fee
Toyama: Consultant, Consulting fee
Viamet: Consultant and Scientific Advisor, Consulting fee

A. Boggild, None

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

Sponsoring Societies:

© 2014, All Rights Reserved.

Follow IDWeek